journal
Journals Critical Reviews in Oncology/h...

Critical Reviews in Oncology/hematology

https://read.qxmd.com/read/38642726/what-is-the-role-of-physical-exercise-in-the-era-of-cancer-prehabilitation-a-systematic-review
#1
REVIEW
Nicole Del Bianco, Anita Borsati, Linda Toniolo, Christian Ciurnielli, Lorenzo Belluomini, Jessica Insolda, Marco Sposito, Michele Milella, Federico Schena, Sara Pilotto, Alice Avancini
PURPOSE: Exercise before surgery, as part of prehabilitation, aiming to enhance patients' functional and physiological capacity, has become widespread, necessitating an in-depth understanding. METHODS: A systematic search was conducted on Pubmed, Cochrane, and Scopus to examine the effect of exercise as prehabilitation, alone or in combination with other interventions, in patients with cancer. Interventional studies applying a single-arm, randomized controlled, or nonrandomized design were included...
April 18, 2024: Critical Reviews in Oncology/hematology
https://read.qxmd.com/read/38641134/research-update-for-ferroptosis-and-cholangiocarcinoma
#2
REVIEW
Shengfeng Fu, Qinyang Zhang, Changhe Zhang
Cholangiocarcinoma (CCA) is the second most common hepatobiliary malignancy after hepatocellular carcinoma. Due to the poor treatment effect and high mortality rate of CCA, it is of great significance to explore new therapeutic targets. Ferroptosis is a type of cell death caused by iron-dependent cell oxidative injury, which is closely related to the occurrence and development of numerous diseases. Novel ideas for the prevention and treatment of related diseases have been provided by ferroptosis, which has become a focus of research in recent years...
April 17, 2024: Critical Reviews in Oncology/hematology
https://read.qxmd.com/read/38626848/the-crosstalk-between-oncogenic-signaling-and-ferroptosis-in-cancer
#3
REVIEW
Qianghu Pang, Zhirou Tang, Lianxiang Luo
Ferroptosis, a novel form of cell death regulation, was identified in 2012. It is characterized by unique features that differentiate it from other types of cell death, including necrosis, apoptosis, autophagy, and pyroptosis. Ferroptosis is defined by an abundance of iron ions and lipid peroxidation, resulting in alterations in subcellular structures, an elevation in reactive oxygen species (ROS), a reduction in glutathione (GSH) levels, and an augmentation in Fe (II) cytokines. Ferroptosis, a regulated process, is controlled by an intricate network of signaling pathways, where multiple stimuli can either enhance or hinder the process...
April 16, 2024: Critical Reviews in Oncology/hematology
https://read.qxmd.com/read/38626849/the-involvement-of-ros-regulated-programmed-cell-death-in-hepatocellular-carcinoma
#4
REVIEW
Hanchen Cai, Ziqi Meng, Fujun Yu
Reactive oxidative species (ROS) is a crucial factor in the regulation of cellular biological activity and function, and aberrant levels of ROS can contribute to the development of a variety of diseases, particularly cancer. Numerous discoveries have affirmed that this process is strongly associated with "programmed cell death (PCD)," which refers to the suicide protection mechanism initiated by cells in response to external stimuli, such as apoptosis, autophagy, ferroptosis, etc. Research has demonstrated that ROS-induced PCD is crucial for the development of hepatocellular carcinoma (HCC)...
April 14, 2024: Critical Reviews in Oncology/hematology
https://read.qxmd.com/read/38621469/trastuzumab-deruxtecan-in-breast-cancer
#5
REVIEW
Miguel Martín, Atanasio Pandiella, Emilio Vargas-Castrillón, Elena Díaz-Rodríguez, Teresa Iglesias-Hernangómez, Concha Martínez Cano, Inés Fernández-Cuesta, Elena Winkow, Maria Francesca Perelló
Trastuzumab deruxtecan (T-DXd) is an antibody-drug conjugate (ADC) consisting of a humanised, anti-human epidermal growth factor receptor 2 (HER2) monoclonal antibody covalently linked to a topoisomerase I inhibitor cytotoxic payload (DXd). The high drug-to-antibody ratio (8:1) ensures a high DXd concentration is delivered to target tumour cells, following internalisation of T-DXd and subsequent cleavage of its tetrapeptide-based linker. DXd's membrane-permeable nature enables it to cross cell membranes and potentially exert antitumour activity on surrounding tumour cells regardless of HER2 expression...
April 13, 2024: Critical Reviews in Oncology/hematology
https://read.qxmd.com/read/38615869/bortezomib-induced-peripheral-neuropathy-clinical-features-molecular-basis-and-therapeutic-approach
#6
REVIEW
Yang Yang, Bing Zhao, Hongli Lan, Jinbing Sun, Guoli Wei
Bortezomib is the first-line standard and most effective chemotherapeutic for multiple myeloma; however, bortezomib-induced peripheral neuropathy (BIPN) severely affects the chemotherapy regimen and has long-term impact on patients under maintenance therapy. The pathogenesis of BIPN is poorly understood, and basic research and development of BIPN management drugs are in early stages. Besides chemotherapy dose reduction and regimen modification, no recommended prevention and treatment approaches are available for BIPN apart from the International Myeloma Working Group guidelines for peripheral neuropathy in myeloma...
April 13, 2024: Critical Reviews in Oncology/hematology
https://read.qxmd.com/read/38614268/what-is-the-association-of-preoperative-biopsy-with-recurrence-and-survival-in-retroperitoneal-sarcoma-a-systematic-review-by-the-australia-and-new-zealand-sarcoma-association-clinical-practice-guidelines-working-party
#7
REVIEW
Stephanie Webster, Ana Cristina Vargas, Fiona Maclean, Jennifer Vu, Elissa Tong, David Coker, Iain Ward, Elizabeth A Connolly, Deborah Di-Xin Zhou, Jasmine Mar, Smaro Lazarakis, David E Gyorki, Angela M Hong
Preoperative biopsy for retroperitoneal sarcoma (RPS) enables appropriate multidisciplinary treatment planning. A systematic review of literature from 1990 to June 2022 was conducted using the population, intervention, comparison and outcome model to evaluate the local recurrence and overall survival of preoperative biopsy compared to those that had not. Of 3192 studies screened, five retrospective cohort studies were identified. Three reported on biopsy needle tract seeding, with only one study reporting biopsy site recurrence of 2 %...
April 13, 2024: Critical Reviews in Oncology/hematology
https://read.qxmd.com/read/38615873/recent-strategies-to-overcome-breast-cancer-resistance
#8
REVIEW
Muhammad Muzamil Khan, Satya Siva Kishan Yalamarty, Bharat Ashok Rajmalani, Nina Filipczak, Vladimir P Torchilin
Breast cancer is potentially a lethal disease and a leading cause of death in women. Chemotherapy and radiotherapy are the most frequently used treatment options. Drug resistance in advanced breast cancer limits the therapeutic output of treatment. The leading cause of resistance in breast cancer is endocrine and hormonal imbalance, particularly in triple negative and HER2 positive breast cancers. The efflux of drugs due to p-gp's activity is another leading cause of resistance. Breast cancer resistant protein also contributes significantly...
April 12, 2024: Critical Reviews in Oncology/hematology
https://read.qxmd.com/read/38615872/n6-methyladenosine-dependent-signaling-in-colorectal-cancer-functions-and-clinical-potential
#9
REVIEW
Shaojun Liu, Min Liu, Yuxuan Li, Qing Song
Colorectal cancer (CRC) ranks as the third most prevalent malignancy worldwide. Despite the gradual expansion of therapeutic options for CRC, its clinical management remains a formidable challenge. And, because of the current dearth of technical means for early CRC screening, most patients are diagnosed at an advanced stage. Therefore, it is imperative to develop novel diagnostic and therapeutic tools for this disease. N6-methyladenosine (m6A), the predominant RNA modification in eukaryotes, can be recognized by m6A-specific methylated reading proteins to modulate gene expression...
April 12, 2024: Critical Reviews in Oncology/hematology
https://read.qxmd.com/read/38615871/the-new-era-of-lung-cancer-therapy-combining-immunotherapy-with-ferroptosis
#10
REVIEW
Yawen Li, Halahati Tuerxun, Yixin Zhao, Xingyu Liu, Xi Li, Shuhui Wen, Yuguang Zhao
Ferroptosis is an unconventional programmed cell death mode caused by phospholipid peroxidation dependent on iron. Emerging immunotherapies (especially immune checkpoint inhibitors) have the potential to enhance lung cancer patients' long-term survival. Although immunotherapy has yielded significant positive applications in some patients, there are still many mechanisms that can cause lung cancer cells to evade immunity, thus leading to the failure of targeted therapies. Immune-tolerant cancer cells are insensitive to conventional death pathways such as apoptosis and necrosis, whereas mesenchymal and metastasis-prone cancer cells are particularly vulnerable to ferroptosis, which plays a vital role in mediating immune tolerance resistance by tumors and immune cells...
April 12, 2024: Critical Reviews in Oncology/hematology
https://read.qxmd.com/read/38615870/a-practical-algorithm-for-acute-myeloid-leukaemia-diagnosis-following-the-updated-2022-classifications
#11
REVIEW
Matteo Giovanni Della Porta, Giovanni Martinelli, Alessandro Rambaldi, Alessandra Santoro, Maria Teresa Voso
Disease classification of complex and heterogenous diseases, such as acute myeloid leukaemia (AML), is continuously updated to define diagnoses, appropriate treatments, and assist research and education. Recent availability of molecular profiling techniques further benefits the classification of AML. The World Health Organization (WHO) classification of haematolymphoid tumours and the International Consensus Classification of myeloid neoplasms and acute leukaemia from 2022 are two updated versions of the WHO 2016 classification...
April 12, 2024: Critical Reviews in Oncology/hematology
https://read.qxmd.com/read/38614270/association-of-pd-l1-expression-with-survival-benefit-from-pd-1-pd-l1-inhibitors-in-advanced-cancer-systematic-review-and-meta-analysis-of-phase-iii-randomized-clinical-trials
#12
REVIEW
Xiaohong Kuang, Run Xu, Jian Li
BACKGROUND: Whether PD-L1 testing is needed to identify patients receiving PD-1/PD-L1 inhibitors is an area of debate. METHODS: PubMed and Embase were searched for phase III randomized clinical trials. We assessed the heterogeneity of overall survival (OS) between patients with high and low PD-L1 expression using an interaction test. RESULTS: Seventy studies representing 44791 patients were included. Both the CPS and TPS can predict better survival from anti-PD-1/PD-L1 therapy in patients with high PD-L1 expression...
April 11, 2024: Critical Reviews in Oncology/hematology
https://read.qxmd.com/read/38614269/c-reactive-protein-crp-as-a-prognostic-biomarker-in-patients-with-urothelial-carcinoma-a-systematic-review-and-meta-analysis
#13
REVIEW
Yu Fujiwara, Alexander B Karol, Himanshu Joshi, Emma Reford, Sudeh Izadmehr, Deborah B Doroshow, Matthew D Galsky
C-reactive protein (CRP) may reflect a pro-inflammatory tumor microenvironment and could represent a biomarker to select patients with urothelial carcinoma more likely to benefit from therapies directed at modulating tumor-promoting inflammation. We performed a systematic review to evaluate survival outcomes based on pre-treatment CRP values in urothelial carcinoma. The hazard ratios (HRs) of survival such as overall survival (OS) and progression-free survival (PFS) between groups with high versus low CRP values were pooled by the random-effect model meta-analyses...
April 11, 2024: Critical Reviews in Oncology/hematology
https://read.qxmd.com/read/38614267/potential-therapeutic-targets-in-myeloid-cell-therapy-for-overcoming-chemoresistance-and-immune-suppression-in-gastrointestinal-tumors
#14
REVIEW
Jiawei Fan, Jianshu Zhu, He Zhu, Hong Xu
In the tumor microenvironment (TME), myeloid cells play a pivotal role. Myeloid-derived immunosuppressive cells, including tumor-associated macrophages (TAMs) and myeloid-derived suppressor cells (MDSCs), are central components in shaping the immunosuppressive milieu of the tumor. Within the TME, a majority of TAMs assume an M2 phenotype, characterized by their pro-tumoral activity. These cells promote tumor cell growth, angiogenesis, invasion, and migration. In contrast, M1 macrophages, under appropriate activation conditions, exhibit cytotoxic capabilities against cancer cells...
April 11, 2024: Critical Reviews in Oncology/hematology
https://read.qxmd.com/read/38614266/tumor-mutational-burden-in-colorectal-cancer-implications-for-treatment
#15
REVIEW
Adriana Marques, Patrícia Cavaco, Carla Torre, Bruno Sepodes, João Rocha
Although immune checkpoint inhibitors have revolutionized the treatment of several advanced solid cancers, in colorectal cancer, the transformative benefit of these innovative medicines is currently limited to those with deficient mismatch repair or high microsatellite instability. Tumor mutational burden (TMB) has emerged as a potential predictor of immunotherapy benefit, but the lack of standardization in its assessment and reporting has hindered the introduction of this biomarker in routine clinical practice...
April 11, 2024: Critical Reviews in Oncology/hematology
https://read.qxmd.com/read/38608913/prognostic-and-therapeutic-potential-of-stat3-opportunities-and-challenges-in-targeting-hpv-mediated-cervical-carcinogenesis
#16
REVIEW
Divya Janjua, Kulbhushan Thakur, Nikita Aggarwal, Apoorva Chaudhary, Joni Yadav, Arun Chhokar, Tanya Tripathi, Udit Joshi, Anna Senrung, Alok Chandra Bharti
Cervical cancer (CaCx) ranks as the fourth most prevalent cancer among women globally. Persistent infection of high-risk human papillomaviruses (HR-HPVs) is major etiological factor associated with CaCx. Signal Transducer and Activator of Transcription 3 (STAT3), a prominent member of the STAT family, has emerged as independent oncogenic driver. It is a target of many oncogenic viruses including HPV. How STAT3 influences HPV viral gene expression or gets affected by HPV is an area of active investigation. A better understanding of host-virus interaction will provide a prognostic and therapeutic window for CaCx control and management...
April 10, 2024: Critical Reviews in Oncology/hematology
https://read.qxmd.com/read/38588967/role-of-extracellular-vesicles-in-castration-resistant-prostate-cancer
#17
REVIEW
Chaoyu Liao, Zeyu Huang, Jingui Liu, Min Deng, Leyi Wang, Yutong Chen, Jia Li, Jiang Zhao, Xing Luo, Jingzhen Zhu, Qingjian Wu, Weihua Fu, Bishao Sun, Ji Zheng
Prostate cancer (PCa) is a common health threat to men worldwide, and castration-resistant PCa (CRPC) is the leading cause of PCa-related deaths. Extracellular vesicles (EVs) are lipid bilayer compartments secreted by living cells that are important mediators of intercellular communication. EVs regulate the biological processes of recipient cells by transmitting heterogeneous cargoes, contributing to CRPC occurrence, progression, and drug resistance. These EVs originate not only from malignant cells, but also from various cell types within the tumor microenvironment...
April 6, 2024: Critical Reviews in Oncology/hematology
https://read.qxmd.com/read/38583546/a-systematic-review-and-meta-analysis-of-the-effectiveness-of-primary-thromboprophylaxis-in-acute-lymphoblastic-leukemia-during-early-phase-therapy-including-asparaginase-or-its-prolonged-form
#18
REVIEW
Zhongbo Hu, Yogindra Persaud, Sanjay Ahuja
Asparaginase is essential in the initial management of acute lymphoblastic leukemia (ALL) but frequently leads to venous thromboembolism (VTE). Using anticoagulants for primary VTE prevention has been studied with no consensus. We conducted a systematic literature search in PubMed, Scopus, and Web of science and performed random-effect meta-analysis using Mantel-Haenszel method in RevMan 5.4 to analyze primary pharmacological thromboprophylaxis during asparaginase treatment in early-phase (induction, consolidation, or intensification phase) therapy in patients with ALL with all ages and followed with subgroup analysis by age...
April 5, 2024: Critical Reviews in Oncology/hematology
https://read.qxmd.com/read/38582227/patient-reported-outcomes-in-randomized-clinical-trials-of-systemic-therapy-for-advanced-soft-tissue-sarcomas-in-adults-a-systematic-review
#19
REVIEW
Evelyne Roets, Winette van der Graaf, Bauke H G van Riet, Rick L Haas, Eugenie Younger, Francesco Sparano, Roger Wilson, Stevie van der Mierden, Neeltje Steeghs, Fabio Efficace, Olga Husson
BACKGROUND: This systematic review evaluates reporting of patient-reported outcomes (PROs) within randomized clinical trials (RCTs) for advanced soft tissue sarcoma (STS) patients. METHODS: A systematic literature search from January 2000 - August 2022 was conducted for phase II/III RCTs evaluating systemic treatments in adult patients with advanced STS. Quality of PRO reporting was assessed using the CONSORT PRO extension. RESULTS: Out of 7294 abstracts, 59 articles were included; comprising 43 RCTs...
April 4, 2024: Critical Reviews in Oncology/hematology
https://read.qxmd.com/read/38580184/circulating-biomarkers-as-predictors-of-response-to-immune-checkpoint-inhibitors-in-nsclc-are-we-on-the-right-path
#20
REVIEW
Calogera Claudia Spagnolo, Francesco Pepe, Giuliana Ciappina, Francesco Nucera, Paolo Ruggeri, Andrea Squeri, Desirèe Speranza, Nicola Silvestris, Umberto Malapelle, Mariacarmela Santarpia
Immune checkpoints inhibitors (ICIs) have markedly improved the therapeutic management of advanced NSCLC and, more recently, they have demonstrated efficacy also in the early-stage disease. Despite better survival outcomes with ICIs compared to standard chemotherapy, a large proportion of patients can derive limited clinical benefit from these agents. So far, few predictive biomarkers, including the programmed death-ligand 1 (PD-L1), have been introduced in clinical practice. Therefore, there is an urgent need to identify novel biomarkers to select patients for immunotherapy, to improve efficacy and avoid unnecessary toxicity...
April 3, 2024: Critical Reviews in Oncology/hematology
journal
journal
20089
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.